Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Red Cross Offers Helpful Water Safety Tips As Holiday Weekend Approaches
Now that the warm weather has arrived, there"s nothing like swimming to help cool you off on a hot summer day. The American Red Cross urges everyone to make water safety a priority over the holiday weekend, whether you are taking a dip in the pool, or spending the day at the beach:
generic viagra online
Xeloda In Combination With Oxaliplatin Shown To Be Effective In Early Colon Cancer
Roche announced results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV). The data prove that XELOX is superior to 5-FU/LV in terms of the time patients live without their cancer being detectable. Purchase zoloft to treat depression.
News of the day
House Education-Labor Panel Passes Health Reform Bill, Rejects Amendments To Ban Abortion Coverage
The House Education and Labor Committee on Friday voted 26-22 to approve the House health reform bill (HR 3200) after adopting 20 amendments, many of which sought to expand the scope of coverage and increase the number of U.S. residents eligible for purchasing coverage through a health insurance exchange, CQ Today reports. The panel voted 19-28 to reject two amendments offered by Rep. Mark Souder (R-Ind.) that would have precluded plans participating in the health insurance exchange -- including the proposed public insurance plan -- from covering abortion services. The committee agreed to allow some existing state and federal programs to obtain waivers from the bill"s requirements. Among the approved amendments was a 400-page amendment by committee Chair George Miller (D-Calif.) that would open the exchange to more small businesses, certain retirees, and families whose premiums and out-of-pocket costs total more than 11% of their income. The amendment was adopted by voice vote (Demirjian, CQ Today, 7/17).
Diagnostics

Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial

Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). This trial is designed to evaluate tolerability and activity when retreating patients who relapse after previously achieving an objective response to brentuximab vedotin. "Data from our phase I clinical trials suggest that patients who responded to brentuximab vedotin, but who relapse after discontinuing their original treatment regimen, may benefit from receiving additional brentuximab vedotin therapy," said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics. "By evaluating brentuximab vedotin in this setting, there is potential to provide further patient benefit and offer an additional therapeutic option for managing relapsed Hodgkin lymphoma and systemic ALCL." The phase II multi-center trial will assess safety and antitumor response to retreatment with brentuximab vedotin. The trial is designed to enroll up to 50 patients with relapsed or refractory Hodgkin lymphoma or systemic ALCL who have previously achieved a complete or partial response to therapy with brentuximab vedotin. Patients will receive 1.8 milligrams per kilogram of brentuximab vedotin every three weeks. Brentuximab vedotin is in an ongoing pivotal trial under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for relapsed or refractory Hodgkin lymphoma and a phase II trial for systemic ALCL. The company also is conducting a phase I clinical trial assessing weekly dosing of brentuximab vedotin. Brentuximab vedotin has received fast track designation from the FDA for Hodgkin lymphoma as well as orphan drug designation in the United States and Europe for both Hodgkin lymphoma and ALCL. Brentuximab vedotin is an ADC comprising an anti-CD30 antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics" proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in targeted cell-killing. Seattle Genetics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009